Wedbush Has Bullish Forecast for CATX Q3 Earnings

Key Points

• Wedbush has raised its Q3 2025 earnings estimate for Perspective Therapeutics (CATX) from ($0.41) to ($0.37) per share, maintaining an "Outperform" rating with a target price of $11.00.
• Other analysts have varying ratings, with Royal Bank Of Canada upgrading its rating to "moderate buy" and increasing the price objective to $16.00.
• The consensus rating for CATX is "Buy" with a target price of $12.56, showcasing positive sentiment despite a recent 7.4% decline in stock price.

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Wedbush raised their Q3 2025 earnings estimates for shares of Perspective Therapeutics in a research report issued to clients and investors on Wednesday, August 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.41). Wedbush has a "Outperform" rating and a $11.00 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Wedbush also issued estimates for Perspective Therapeutics' Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.34) EPS, Q1 2026 earnings at ($0.46) EPS, FY2027 earnings at ($1.71) EPS and FY2028 earnings at ($1.30) EPS.

Other equities analysts have also issued reports about the stock. Royal Bank Of Canada upgraded shares of Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, June 3rd. B. Riley restated a "buy" rating and issued a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Truist Financial decreased their price objective on shares of Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Saturday, July 12th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Trading Down 7.4%

NYSE:CATX opened at $3.61 on Monday. The company's 50-day moving average is $3.76 and its two-hundred day moving average is $2.95. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $16.55.

Institutional Investors Weigh In On Perspective Therapeutics

Several large investors have recently added to or reduced their stakes in CATX. BNP Paribas Financial Markets raised its holdings in shares of Perspective Therapeutics by 227.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 242,610 shares of the company's stock valued at $835,000 after purchasing an additional 168,448 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Perspective Therapeutics by 8.5% in the 2nd quarter. Bank of America Corp DE now owns 327,500 shares of the company's stock valued at $1,127,000 after purchasing an additional 25,697 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Perspective Therapeutics by 44.4% in the 2nd quarter. Federated Hermes Inc. now owns 195,080 shares of the company's stock valued at $671,000 after purchasing an additional 60,019 shares in the last quarter. Walleye Capital LLC raised its holdings in shares of Perspective Therapeutics by 375.8% in the 2nd quarter. Walleye Capital LLC now owns 187,403 shares of the company's stock valued at $645,000 after purchasing an additional 148,013 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Perspective Therapeutics by 118.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company's stock valued at $2,573,000 after purchasing an additional 405,612 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.